hameln pharma ApS: Financial statements 2024
CVR: 39720213
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
hameln pharma ApS (CVR 39720213) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 6,856,814 and a net result of DKK 5,288,671 compared with DKK 2,324,545 the year before. That is an increase of 119% compared with the year before. Equity in the 2024 report amounted to DKK 12,297,205. The solvency ratio was 66%.
- Gross Profit
- DKK 6,856,814
- Profit/Loss
- DKK 5,288,671
- Equity
- DKK 12,297,205
- Total Assets
- DKK 18,628,456
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 6.9 mio. | 5.3 mio. | 12.3 mio. | 0 |
| 2023 | - | 3.1 mio. | 2.3 mio. | 7.4 mio. | 0 |
| 2022 | - | 2.6 mio. | 1.9 mio. | 5 mio. | 0 |
| 2021 | - | 1.9 mio. | 1.4 mio. | 3.2 mio. | 0 |
| 2020 | - | 2.4 mio. | 1.9 mio. | 1.8 mio. | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Hameln pharma ApS has won the tender "Amgros 2025 1.1208.b" issued by Amgros I/S worth 7,330,000 DKK.
Hameln pharma ApS has won the tender "Amgros 2025 2.1310.b" issued by Amgros I/S worth 129,999,998 DKK.
Hameln pharma ApS has won the tender "Amgros 2025 1.1303.b" issued by Amgros I/S worth 14,267,938 DKK.
Hameln pharma ApS has won the tender "Amgros 2025 1.1302.a" issued by Amgros I/S worth 17,702,414 DKK.
Hameln pharma ApS has won the tender "Amgros 2025 1.1205.a" issued by Amgros I/S worth 73,155,425 DKK.
Hameln pharma ApS has won the tender "Amgros 2025 1.1240.a" issued by Amgros I/S worth 13,800,000 DKK.
Hameln pharma ApS has won the tender "Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1301.a" issued by Amgros I/S worth 227,000,000 EUR.
Hameln pharma ApS has won the tender "Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1302.a" issued by Amgros I/S worth 18,750,000 EUR.
Hameln pharma ApS has published its annual report for 2023. Gross profit came to DKK 3,130,279, and the net result was DKK 2,324,545.
About hameln pharma ApS
hameln pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Frank Jahrand and Stephen Allen Watkin. The company is owned by hameln pharma gmbh. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 10,300,176 and a net result of DKK 8,050,599 compared with DKK 5,288,671 the year before. Equity in the 2025 report amounted to DKK 20,334,774.